Warning letters / August 2026
FDA published warning letters in August 2026 to Fresenius Medical Care AG & Co. KGaA, PReye, LLC, Suretec Innovations, LLC, K.C. Pharmaceuticals, Inc., and Safrel Pharmaceuticals LLC. Review the original records before drawing conclusions.
FDA warning letters are public notices of agency concerns and requested correction. A warning letter is not, by itself, a complete enforcement history or a final adjudication of every issue described.
FDA's record is dated August 25, 2026 and identifies the Center for Drug Evaluation and Research as the issuing office. Read the complete letter, reference 730319.
FDA posted the PReye, LLC letter on August 18, 2026. The record identifies the recipient in Wheat Ridge, Colorado and uses reference number 320-26-118. Read the PReye, LLC letter.
The Suretec Innovations, LLC record is dated August 13, 2026. FDA identifies the recipient as the company's president and lists a Las Vegas, Nevada address. Read the Suretec Innovations, LLC letter.
FDA's record says the August 12, 2026 letter summarizes significant Current Good Manufacturing Practice violations involving finished pharmaceuticals. Read the K.C. Pharmaceuticals, Inc. letter.
FDA issued the Safrel Pharmaceuticals LLC letter on August 7, 2026. The record identifies CDER and reference number 320-26-111. Read the Safrel Pharmaceuticals LLC letter.
Save the FDA URL, letter date, reference number, issuing office, and a copy of the original document. Record later response or closeout material separately.
Break the letter into individual observations. For each one, record the responsible owner, affected product or process, corrective action, due date, and evidence needed for verification.
A revised procedure may address an issue, but it does not prove the procedure works. Pair changes with evidence appropriate to the cited issue.
Monitor for response letters, closeout letters, recalls, import actions, or other public updates. Do not label a matter resolved until the relevant record supports that conclusion.
A dated, source-linked index gives compliance and legal teams a review queue. It also reduces a common error: treating the publication date, inspection date, and later response date as if they were the same event.
The FDA's Warning Letters archive is the starting point. Confirm the current record and review the full letter before making a business or regulatory decision.
No. It communicates agency concerns and requested corrections. The full record and later agency communications determine what happened afterward.
Use the direct FDA links in this article and the FDA Warning Letters archive. Confirm the letter date and reference number before citing a record.
Get the weekly FDA source digest. It is a free weekly email with warning-letter, recall, and enforcement notes tied back to public FDA records.